US Pharma MarketingRegeneron’s Pasatru wins FDA approval in ultra-rare ‘stone man disease’
Regeneron’s Pasatru wins FDA approval in ultra-rare ‘stone man disease’ is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Pasatru demonstrated strong efficacy in a Phase III trial, helping patients reduce lesions and flare-ups.
Source: Pharmaceutical Technology